Larazotide Acetate (AT-1001): Complete Research Profile — Zonulin Antagonist, Tight Junction Regulator, and Intestinal Barrier Research Tool (2026)

# Larazotide Acetate (AT-1001): Complete Research Profile — Zonulin Antagonist, Tight Junction Regulator, and Intestinal Barrier Research Tool (2026)

Introduction

Larazotide acetate, also designated AT-1001, is a first-in-class synthetic octapeptide that occupies a unique position in peptide research pharmacology: it acts directly at the zonulin receptor to stabilize intestinal tight junctions and prevent paracellular permeability increases. Originally developed from structural motifs of the Vibrio cholerae zonula occludens toxin (Zot), larazotide has become an indispensable research tool for investigators studying the zonulin pathway, intestinal barrier dysfunction, and the downstream inflammatory cascades that connect increased gut permeability to autoimmune, metabolic, and infectious disease states.

Unlike most gut-targeted peptides that act on receptors or channels to produce a systemic pharmacological effect, larazotide operates via a fundamentally different logic: it competes with endogenous zonulin for receptor occupancy, thereby preventing the cytoskeletal rearrangements that open paracellular spaces between epithelial cells. This locally acting, non-systemically absorbed mechanism has made AT-1001 one of the most scientifically informative research compounds for understanding how the intestinal epithelial barrier is regulated and dysregulated in disease.

This profile covers the molecular biology of larazotide acetate, its mechanism of action through the zonulin/Zot pathway, the spectrum of disease models in which it has been investigated as a research probe, and its practical utility as a laboratory reagent for researchers studying barrier function, inflammation, and paracellular transport.

---

Structure, Biochemistry, and Physical Properties

Amino Acid Sequence

Larazotide acetate is an eight-amino-acid (octapeptide) synthetic compound with the primary sequence:

H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH

The acetate salt form (CAS 881851-50-9) is the standard research-grade formulation, with a molecular weight of approximately 698.8 Da for the free peptide backbone and approximately 1,000–1,024 Da when the full acetate salt form and any modifications are accounted for. The peptide adopts a relatively unstructured conformation in solution, consistent with its luminal mode of action that requires receptor-binding rather than a rigid structural pharmacophore.

Origin and Derivation

The sequence was derived from a functionally active region of the Vibrio cholerae Zot protein, which was discovered to regulate intestinal tight junction permeability via the same endogenous receptor pathway used by human zonulin. This derivation is counterintuitive — a toxin fragment becoming a receptor antagonist — but it reflects the competitive-antagonism logic at the heart of larazotide's mechanism: by occupying the receptor without triggering the downstream permeabilizing cascade, larazotide blocks endogenous zonulin from opening tight junctions.

Stability and Formulation

Like most octapeptides, larazotide acetate is subject to enzymatic degradation in the gastrointestinal lumen, a property that paradoxically supports its safety profile: systemic absorption is negligible because the peptide is cleaved before it can traverse the enterocyte layer. Research formulations are typically lyophilized powder stored at −20°C, reconstituted in sterile water or phosphate-buffered saline for in vitro assays, or prepared as oral capsules/solutions for in vivo preclinical and clinical models.

---

The Zonulin Pathway: Biological Context

What Is Zonulin?

Zonulin is an endogenous human protein — the only known physiological modulator of intercellular tight junctions capable of reversibly increasing intestinal paracellular permeability. Structurally, human zonulin is complement C3b (or closely related proteins in the C3/coagulation cascade family), though this identification remains an active area of refinement in the literature. Functionally, zonulin is released from intestinal epithelial cells in response to specific luminal stimuli including gliadin (the immunogenic component of wheat gluten), certain gut bacteria, and other pattern-recognition triggers.

The critical 2011 review by Fasano in Clinical Reviews in Allergy & Immunology (PMC3384703) established the zonulin pathway as a unifying mechanism linking intestinal permeability to a broad spectrum of inflammatory and autoimmune diseases. According to this model, stimulus-driven zonulin release activates a receptor-mediated signaling cascade on intestinal epithelial cells involving PAR2 transactivation of EGFR, phospholipase C, IP-3 generation, PKCα activation, and ultimately myosin light chain kinase (MLCK) phosphorylation — which physically pulls tight junction-associated actin filaments apart, widening paracellular spaces.

Why Tight Junctions Matter for Research

Tight junctions (TJs) are multiprotein complexes at the apical lateral surface of epithelial and endothelial cells. The core structural elements include claudins (1, 2, 3, 4, 5, 7, 8), occludin, junction adhesion molecules (JAMs), and the scaffold proteins zonula occludens-1, -2, and -3 (ZO-1, ZO-2, ZO-3). These proteins form a seal that restricts paracellular transport of macromolecules, antigens, microbial products, and inflammatory mediators between the gut lumen and the systemic circulation.

When TJs open — whether through zonulin signaling, cytokine-induced phosphorylation cascades, or mechanical stress — the resulting paracellular leak allows antigen exposure that drives inflammatory responses. The clinical relevance ranges from acute events (cholera-associated fluid secretion) to chronic, low-grade permeability increases implicated in autoimmune disease, metabolic syndrome, neuroinflammation, and infectious sequelae. Understanding and controlling this permeability is therefore a central goal of intestinal barrier research.

---

Mechanism of Action

Zonulin Receptor Antagonism

Larazotide acetate's primary mechanism is competitive antagonism at the zonulin receptor on intestinal epithelial cells. By occupying the receptor, larazotide prevents endogenous zonulin from binding and initiating the PAR2/EGFR/PKCα/MLCK cascade described above. In the absence of downstream MLCK activation, actin filament tension is reduced, tight junction proteins remain in their assembled configuration, and paracellular permeability is maintained or restored toward baseline.

This mechanism has been confirmed in both in vitro studies using Caco-2 and T84 intestinal epithelial cell monolayers (measuring transepithelial electrical resistance as a barrier function surrogate) and in vivo preclinical models using lactulose-to-mannitol ratio as a validated gut permeability readout.

Promotion of Tight Junction Assembly

Beyond simple antagonism, larazotide acetate has been observed to actively promote TJ assembly. In studies on intestinal epithelial cells exposed to permeabilizing stimuli (gliadin, interferon-gamma, tumor necrosis factor-alpha), AT-1001 accelerates the relocalization of ZO-1, claudin-1, and occludin to the tight junction complex, facilitating tighter intercellular apposition. This dual action — preventing disassembly and promoting reassembly — makes larazotide a more potent barrier-restoring tool than simple receptor blockade would predict. The mechanisms underlying this pro-assembly effect likely involve indirect effects on actin cytoskeletal dynamics downstream of reduced MLCK activity.

Luminal Restriction and Minimal Systemic Bioavailability

A pharmacokinetically distinctive feature of larazotide is its near-complete luminal restriction. After oral or intraluminal administration, the peptide is detected in intestinal tissue but not in measurable concentrations systemically. This property, confirmed in human pharmacokinetic studies, means larazotide functions essentially as a luminal probe of zonulin signaling rather than a systemic drug. For researchers, this creates a clean dissociation between gut barrier effects (attributable to larazotide) and systemic anti-inflammatory effects (attributable to downstream consequences of improved barrier integrity).

---

Research Applications in Disease Models

Celiac Disease Research

The largest body of research on larazotide acetate has emerged from celiac disease (CeD), where gliadin-triggered zonulin release is a well-characterized initiating event in immune activation. Key preclinical studies established that AT-1001 reduces gliadin-induced permeability increases in Caco-2 monolayers and animal models, providing mechanistic proof of concept for TJ-targeted intervention.

Multiple clinical research studies followed:

Kelly et al. (2013) in Alimentary Pharmacology & Therapeutics (PMID: 22825365) reported a randomized, double-blind study in which CeD subjects underwent a short-term gluten challenge while receiving larazotide or placebo. AT-1001 significantly reduced lactulose-to-mannitol ratio increases (a validated measure of intestinal permeability) compared to placebo, providing clinical validation of the zonulin-blocking mechanism in humans.

Leffler et al. (2015) in Gastroenterology (PMC: PMC4446229) conducted a Phase IIb randomized controlled trial of larazotide acetate (0.5 mg, 1 mg, 2 mg thrice daily) in CeD patients with persistent symptoms on a gluten-free diet. The 0.5 mg dose met the primary endpoint (reduction in CeD Patient Reported Outcome symptom score), demonstrating that barrier-targeted intervention can reduce GI symptomatology even in the absence of ongoing gluten exposure — implicating residual zonulin pathway activation as a driver of symptoms in treated CeD.

Diagnostic and therapeutic implications of zonulin as a biomarker were reviewed by Fasano in Clinical Gastroenterology and Hepatology (PMID: 22902773), establishing the conceptual framework for larazotide's research utility beyond CeD into any condition characterized by zonulin pathway dysregulation.

Despite these positive Phase II findings, the Phase III CedLara trial (NCT03569007) in a larger CeD population did not replicate the primary endpoint difference, leading 9 Meters Biopharma to discontinue the CeD indication in 2022. This outcome has been discussed in the research community as potentially reflecting patient heterogeneity, endpoint selection, or the complexity of isolating permeability-driven symptomatology from other CeD disease processes.

Autoimmune Disease Research

The zonulin pathway hypothesis — that increased intestinal permeability serves as a driver of systemic immune activation in autoimmune diseases — has generated significant research interest in whether larazotide could reduce disease progression by sealing the barrier upstream of antigen exposure and inflammatory cascades.

A comprehensive 2021 review in Expert Opinion on Investigational Drugs (PMID: 33397225) catalogued the preclinical and translational evidence for larazotide (AT-1001) across conditions including:

• •Type 1 Diabetes (T1D): NOD mouse models showed that zonulin levels rise before islet autoimmunity manifests, and larazotide treatment in these models delayed or reduced the incidence of T1D. The hypothesis is that gliadin-triggered zonulin release permits islet antigen exposure to gut-associated lymphoid tissue, initiating the autoimmune cascade.

• •Inflammatory Bowel Disease (IBD): Both Crohn's disease and ulcerative colitis are characterized by elevated zonulin and increased intestinal permeability, and larazotide has been investigated as a barrier-restoring adjunct in experimental colitis models.

• •Rheumatoid Arthritis: A landmark study in Nature Communications in 2020 (DOI: 10.1038/s41467-020-15831-7) demonstrated that targeting zonulin and intestinal barrier function with larazotide-related approaches reduced the onset of arthritis in preclinical models, implicating the gut-joint axis as a research target in inflammatory arthritis.

• •Multiple Sclerosis: Elevated serum zonulin has been documented in MS patients, and animal models suggest intestinal permeability precedes or accompanies neuroinflammatory events, making larazotide a research probe for investigating gut-brain immune axis pathways.

• •Non-Celiac Gluten Sensitivity (NCGS): NCGS is characterized by gluten-triggered GI and extra-intestinal symptoms in the absence of CeD or wheat allergy. Zonulin pathway activation is proposed as a mechanism, and larazotide has been studied as a model compound for understanding barrier regulation in this condition.

COVID-19, Long COVID, and MIS-C Research

A particularly active area of recent larazotide research has involved SARS-CoV-2 and its sequelae, driven by observations that:

1. COVID-19 causes zonulin-mediated gut permeability increases with SARS-CoV-2 viral antigen trafficking from the gut lumen into circulation

2. Multisystem Inflammatory Syndrome in Children (MIS-C) is characterized by gut breach and systemic viral antigenemia

3. Long COVID features persistent gut permeability and viral antigenemia in a subset of patients

Zonulin antagonist larazotide in MIS-C: A 2022 case series in Critical Care Explorations (PMC: PMC8860335) described pediatric MIS-C patients treated with larazotide as an adjunct to standard care. Treated patients showed faster antigenemia clearance and symptom resolution compared to historical controls, raising the hypothesis that gut barrier sealing reduces ongoing viral antigen translocation driving the hyperinflammatory state.

Science Translational Medicine (2025): A 2025 study in Science Translational Medicine (DOI: 10.1126/scitranslmed.adu4284) expanded this work, demonstrating viral spike antigen clearance and augmented recovery in children with post-COVID MIS-C treated with larazotide, providing mechanistic data supporting the gut-permeability-to-antigenemia hypothesis.

Long COVID clinical trials: As of 2023–2026, multiple clinical trials have evaluated AT-1001 in Long COVID with SARS-CoV-2 antigenemia (NCT05747534), reflecting the translational momentum from MIS-C observations to adult post-COVID research.

Acute Lung Injury and Respiratory Barriers: Beyond gut-focused research, larazotide's mechanism has been extended to respiratory epithelial barrier contexts. 9 Meters Biopharma received US patent protection for larazotide in acute respiratory distress and acute lung injury, based on the observation that loss of epithelial barrier integrity in the lung drives interstitial edema and inflammatory mediator translocation relevant to ARDS pathophysiology. This application broadens larazotide from a purely gut-centric research tool to a pan-epithelial barrier biology probe.

Kawasaki Disease Research

The Expert Opinion 2021 review (PMID: 33397225) also documented larazotide research in Kawasaki disease models, where gut vascular barrier disruption and systemic vasculitis share mechanistic features with MIS-C — further supporting the concept that the gut barrier is a central regulatory node for systemic inflammatory diseases.

---

Research Comparisons with Other Barrier Peptides

Larazotide Acetate vs. BPC-157

BPC-157 (Body Protection Compound 157) is a 15-amino acid peptide derived from the body protection compound of gastric juice, widely studied for its GI mucosal protective and systemic healing effects. Both BPC-157 and larazotide are used in intestinal barrier research, but their mechanisms are fundamentally different:

For researchers studying the specific zonulin pathway, larazotide is the more mechanistically defined tool. For broader mucosal healing and multi-system regenerative biology, BPC-157 remains the preferred research probe.

Larazotide Acetate vs. Other Gut Permeability Research Tools

Zonulin ELISAs, lactulose-mannitol ratio assays, and transepithelial electrical resistance (TEER) measurement provide readouts of barrier function; larazotide serves as a mechanistic intervention tool to distinguish zonulin-dependent from zonulin-independent permeability mechanisms. Researchers can combine larazotide with barrier function assays to dissect pathway-specific contributions to intestinal leakiness.

---

Laboratory Utility and Research Protocols

In Vitro Tight Junction Assays

Larazotide acetate is commonly used in cell-culture barrier models at concentrations of 0.1–10 µM:

• •TEER measurement: Applied apically to Caco-2, T84, or HT-29/MTX monolayers prior to or concurrent with permeabilizing stimuli (gliadin, cytokines, lipopolysaccharide, hydrogen peroxide). AT-1001 dose-dependently maintains or restores TEER.
• •Fluorescein flux assays: Paracellular permeability tracked with fluorescently labeled dextrans or small molecules; larazotide treatment reduces apical-to-basal flux.
• •Tight junction protein immunolocalization: Confocal microscopy of ZO-1, claudin-1, and occludin localization before and after larazotide treatment, demonstrating junctional reassembly.
• •Actin cytoskeleton visualization: Phalloidin staining reveals actin stress fiber patterns associated with MLCK activity; larazotide-treated monolayers show reduced perijunctional actin ring disruption.

In Vivo Models

Preclinical researchers have used AT-1001 in rodent models of:

• •Gliadin-induced permeability: Oral larazotide (0.5–2 mg/kg/day) blocks gliadin-provoked lactulose-mannitol ratio increases
• •NOD mouse T1D: Reduces islet autoimmunity incidence when administered during the pre-diabetic period
• •TNBS or DSS colitis: Reduces mucosal permeability and inflammatory markers in experimental IBD models
• •Post-COVID antigenemia: Recent MIS-C and Long COVID murine models have used AT-1001 to examine gut barrier sealing and antigen clearance

Reconstitution and Storage

• •Lyophilized powder: Store at −20°C, protected from moisture and light; stable for ≥2 years under appropriate conditions
• •Reconstitution: Dissolve in sterile PBS or distilled water at ≤1 mg/mL; filter-sterilize (0.22 µm) for cell culture
• •Working solutions: Prepare fresh or aliquot and freeze; avoid repeated freeze-thaw cycles (>3)
• •Vehicle control: PBS matched for pH and osmolarity is the standard vehicle control in larazotide barrier assays
• •pH sensitivity: Maintain neutral pH (6.5–7.5) for optimal stability

---

Safety Profile in Research Contexts

Human safety data are available from multiple Phase I and Phase II trials in CeD and Long COVID, establishing that oral larazotide acetate at doses of 0.5–4 mg three times daily is generally well-tolerated, with adverse event profiles similar to placebo. The dominant safety advantage is its non-systemic absorption profile, which eliminates the systemic immunosuppression risks associated with conventional anti-inflammatory approaches.

For in vitro and in vivo research use (RUO), larazotide at standard laboratory concentrations shows no cytotoxicity in intestinal epithelial cell models. In vivo rodent studies demonstrate no significant hepatotoxicity, nephrotoxicity, or systemic inflammatory activation at research doses.

---

Research Design Considerations

Researchers using larazotide as a mechanistic probe should consider several important factors:

Zonulin assay interpretation: Commercial zonulin ELISAs have shown variable specificity and may cross-react with complement C3 fragments and other proteins. Researchers should interpret zonulin measurements alongside functional permeability assays rather than relying on ELISA data alone, as discussed in emerging critical literature on zonulin measurement methodology.

Dose-response non-linearity: Phase IIb CeD trials identified 0.5 mg (not the highest dose) as the most effective dose, suggesting bell-shaped dose-response curves that may reflect receptor occupancy saturation or compensatory pathway activation at higher concentrations.

Disease state context: Larazotide effects on barrier function are most pronounced in settings of active zonulin pathway activation. Baseline TEER or permeability in unstimulated cells or non-inflammatory animal models may show minimal changes, potentially masking the peptide's research utility if appropriate challenge stimuli are not incorporated into study design.

Comparison to genetic tools: CRISPR-based claudin knockouts, ZO-1 siRNA, and transgenic zonulin-overexpressing mice provide complementary genetic approaches; pharmacological larazotide intervention offers the translational advantage of reversibility and clinical precedent.

---

Current Research Landscape (2025–2026)

The trajectory of larazotide research has moved well beyond celiac disease into a broader vision of gut-permeability-mediated disease biology. Active research frontiers as of 2026 include:

• •Long COVID and antigenemia: Multiple trials evaluating AT-1001 in patients with persistent SARS-CoV-2 antigenemia and post-acute sequelae (Long COVID)
• •Pediatric MIS-C mechanistic studies: Building on the 2025 Science Translational Medicine findings to characterize biomarkers of gut barrier breach and antigen clearance
• •Non-alcoholic fatty liver disease (NAFLD/MASH): Elevated zonulin documented in NAFLD/MASH patients; gut-liver axis permeability as a research target
• •Neurological conditions: Zonulin pathway activation in Alzheimer's disease, Parkinson's disease, and autism spectrum disorder models, with larazotide as a probe for gut-brain axis research
• •Combination strategies: Larazotide as an adjunct to dietary interventions (gluten-free diet, specific carbohydrate diet) in barrier-mediated GI diseases

---

Summary

Larazotide acetate (AT-1001) is a synthetic octapeptide zonulin receptor antagonist that seals intestinal tight junctions by competitively blocking the endogenous permeabilizing protein zonulin from initiating paracellular opening cascades. Derived from a functional motif of the Vibrio cholerae Zot toxin, it acts locally in the intestinal lumen with negligible systemic bioavailability, making it a mechanistically clean research tool for zonulin pathway biology.

With a clinical research record spanning celiac disease, autoimmune diseases (type 1 diabetes, rheumatoid arthritis, IBD, multiple sclerosis), COVID-19-associated MIS-C, Long COVID, and exploratory applications in respiratory epithelial barrier biology, larazotide occupies a central position in intestinal permeability research. Its translational value lies not only in its barrier-sealing mechanism but in its use as a pharmacological dissection tool: by blocking the zonulin pathway specifically, researchers can distinguish zonulin-dependent from zonulin-independent contributions to inflammatory and immune pathology.

This article is for research education purposes only. Larazotide acetate is a research use only (RUO) compound. All applications referenced are investigational laboratory and preclinical/clinical research contexts. No content here constitutes medical advice or clinical protocol guidance.

---

References

1. Fasano A. "Zonulin, regulation of tight junctions, and autoimmune diseases." Clinical Reviews in Allergy & Immunology. 2012. PMC3384703

2. Kelly CP, et al. "A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge." Alimentary Pharmacology & Therapeutics. 2013. PMID: 22825365

3. Leffler DA, et al. "Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial." Gastroenterology. 2015. PMC4446229

4. Fasano A. "Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications." Clinical Gastroenterology and Hepatology. 2012. PMID: 22902773

5. Camilleri M, et al. "Larazotide acetate: a pharmacological peptide approach to tight junction regulation." American Journal of Physiology — Gastrointestinal and Liver Physiology. 2021. PMID: 33881350

6. Sova M, et al. "The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate." Expert Opinion on Investigational Drugs. 2016. PMID: 26770266

7. Morón-Ros S, et al. "The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases." Expert Opinion on Investigational Drugs. 2021. PMID: 33397225

8. Yacyshyn BR, et al. "Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis." Nature Communications. 2020. DOI: 10.1038/s41467-020-15831-7

9. Porkorny M, et al. "Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series." Critical Care Explorations. 2022. PMC8860335

10. Fasano A, et al. "Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide." Science Translational Medicine. 2025. DOI: 10.1126/scitranslmed.adu4284

11. Fasano A. "Intestinal Permeability and Its Regulation by Zonulin: Diagnostic and Therapeutic Implications." Clinical Gastroenterology and Hepatology. 2012. PMID: 22902773